Fortrea Holdings Inc. (FTRE) Stock Price & Analysis
Fortrea Holdings Inc. (FTRE) closed at USD 25.88 on Wednesday, October 28, 2026, up 5.94% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 24.43; the Oct 28, 2026 session ranged USD 24.3–26.16 on volume of 3,587,141 shares. Market capitalization is $2.46B, with a 52-week range of USD 8.55–26.16 (NMS). Source: Nexqual, retrieved October 29, 2026 at 10:41 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FTRE.md
Key facts (FTRE)
- Analysts: Hold (mean 2.69 on a 1–5 scale) (13 analysts), mean target USD 21.71 (range 13.5–26).
Analysts (FTRE)
Consensus Hold (mean 2.69 on a 1–5 scale), 13 analysts; mean target USD 21.71 (low 13.5, high 26).
Key Statistics (as of October 29, 2026 at 10:41 UTC)
| Price | USD 25.88 |
|---|---|
| Change | ▲ 5.94% (up) |
| Previous Close | USD 24.43 |
| Open | USD 24.36 |
| Day Range | USD 24.3 – 26.16 |
| 52-Week Range | USD 8.55 – 26.16 |
| Volume | 3,587,141 shares |
| Market Cap | $2.46B |
| Exchange | NMS |
Analyst Ratings (FTRE)
Wall Street analysts rate FTRE "Hold" based on 13 analysts, with a mean price target of USD 21.71 (range USD 13.5–26), per Nexqual as of October 29, 2026 at 10:41 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 21.71 |
| High Target | USD 26 |
| Low Target | USD 13.5 |
| Buy / Hold / Sell | 7 / 4 / 2 |
From Fortrea Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Fortrea also supports leading large pharmaceutical customers as a preferred provider for services across our range of offerings, including Clinical Pharmacology, Phase I-IV Full Service, Consulting Services, Clinical/Biometrics/Safety FSP, and Hybrid models that combine Full Service and FSP.
- In the course of conducting our business, we have developed, and continue to develop and use, proprietary software, systems, processes, databases and other intellectual property.
- We seek to protect our proprietary and confidential information and trade secrets through confidentiality agreements with employees, customers, and other third parties, as well as through administrative and technical safeguards.
- We believe that our commitment to continuous service and technology innovations combined with Fortrea's tailored approach to serve both biotechnology and large biopharmaceutical companies and experience across more than 20 therapeutic areas enables us to continue to differentiate ourselves from peers in the CRO industry.
Partnerships
- On March 9, 2024, the Company, together with its wholly-owned subsidiary, Fortrea Inc., entered into an Asset Purchase Agreement (the "Purchase Agreement") with Endeavor Buyer LLC, an affiliate of Arsenal Capital Partners, to sell the operations of Fortrea Patient Access Inc. and its subsidiaries and Endpoint Clinical, Inc. and its subsidiaries; which are all collectively referred to as the Enabling Services Segment.
- The insights gathered show consistent alignment with industry benchmarks and demonstrate meaningful progress across key engagement drivers, including collaboration, inclusion, and confidence in leadership.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to comply with the regulations of pharmaceutical and medical device regulatory agencies could result in sanctions and/or remedies against us and have a material adverse effect on us.
- Changes in government regulation or in practices relating to the pharmaceutical, biotechnology, or medical device industries could decrease the need for certain services that we provide.
- Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to our reputation with customers and have a material adverse effect upon our business.
- Failure to comply with federal, state, and foreign laws and regulations could result in substantial penalties and our business, financial condition, results of operations, cash flows, and prospects could be adversely affected.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 10:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt